Jasper Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 13.21 million compared to USD 9.06 million a year ago. Basic loss per share from continuing operations was USD 3.6 compared to USD 2.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.96 USD | +7.72% | +8.53% | +229.02% |
05-20 | Transcript : Jasper Therapeutics, Inc. - Special Call | |
05-13 | Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+229.02% | 364M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- JSPR Stock
- News Jasper Therapeutics, Inc.
- Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022